Therapeutic agents targeting inflammatory pathways, such as TNF-α inhibitors, IL- 12/IL- 23 inhibitors (ustekinumab), and IL- 17/IL- 23 inhibitors, improve psoriasis management and may mitigate CVD risk. Here, TNF is linked to psoriasis.